Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 5/20 | 0.39 |
| ▸ | CCKAR | P32238 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23879600 | 0.87 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL23879572 | 0.86 | MCL1 (0.44) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL23879592 | 0.84 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL23879621 | 0.84 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL23879590 | 0.83 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL23879550 | 0.81 | HPGD (0.40) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL23879538 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL23879649 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL24268101 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL26188539 | 0.79 | KMT2A (0.38) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | ALDH1A1 245/4885KDM4E 3158/4885HPGD 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.